HSPA6 Antibodies

Heat shock 70 kDa protein 6 (HSPA6)

Molecular chaperone implicated in a huge array of cellular processes, such as protection of the proteome from pressure, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. Plays a pivotal role in the protein quality control system, ensuring the right folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation.

This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The affinity for polypeptides is governed by its nucleotide bound state.

Gene Information

Human
Gene Name:	HSPA6
Uniprot:	P17066
Entrez:	3310

Family

Belongs to:
heat shock protein 70 family

Alternative Names

heat shock 70 kDa protein 6; Heat shock 70 kDa protein B'; heat shock 70kD protein 6 (HSP70B'); heat shock 70kDa protein 6 (HSP70B'); HSP70B'

Molecular Weight

Mass (kDA):
71.028 kDA

Genomic Context

Human
Location:	1q23.3
Sequence:	1; NC_000001.11 (161524540..161526894)

Diseases

• Malignant Neoplasms
• Neoplasms
• Melanoma
• Autoimmune Reaction
• Leukemia
• Malignant Neoplasm Of Breast
• Neurodegenerative Disorders
• Leukemia, T-cell
• Malignant Tumor Of Colon
• Diphtheria
• Carcinoma

• Immunologic Deficiency Syndromes
• Multiple Myeloma
• Tumor Angiogenesis
• Innate Immune Response
• Pancreatic Neoplasm

Interacting Proteins

• TERF1

Pathways

• Cell Death
• Cell Cycle
• Cell Growth
• Transport
• Intracellular Transport
• Immune Response
• Endocytosis
• Zinc Ion Homeostasis
• Ion Homeostasis
• Translation
• Protein Refolding

• Innate Immune Response
• Cell Communication
• Angiogenesis
• Wound Healing
• Pathogenesis
• Secretion

PTMs

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HSPA6

Best Uses Of The HSPA6 Marker

The HSPA6 Marker is one of the most important proteins in the human genome. Scientists who are studying its functions can find out if it is the culprit behind lung, ovarian, or prostate cancer. In addition, scientists can submit their research results to gain product credits. This marker is applicable to scientists across the globe. However, it is not as well-known as the HSPA6 protein.

HSPA6 Marker for lung cancer

Among the many immune checkpoint ligands and receptors, the HSPA6 marker for lung cancer is currently a developing immunotherapy biomarker. It was found to be associated with tumor-infiltrating immune cells, stromal score, and ESTIMATE. It also correlated with the expression levels of immune checkpoint receptors and ligands. In the current study, it was found to have positive correlation with HSPA6 expression.

The gene HSPA6 is related to immune cells, cell proliferation, and cell migration. The gene is regulated by the PI3K-AKT signaling pathway, which activates a cascade of downstream substrates. In addition to its role in tumor cells, HSPA6 expression is associated with grade and gender. Moreover, it is associated with invasion. Moreover, it was found to be overexpressed in glioma cells. The expression of HSPA6 was validated by functional in vitro experiments.

Using a Wilcoxon rank sum test, the gene HSPA6 was associated with poor prognosis in TCGA cohort. The prognostic model developed using HSPA6 expression was associated with other relevant clinical factors, including grade and age. Thus, HSPA6 may serve as a poor independent lung cancer biomarker. It has also been shown to predict the progression of lung cancer.

The corresponding mutation in HSPA6 can also be associated with aggressiveness and increased TMB. The gene is also associated with two types of gliomas: low-grade adenocarcinoma, glioblastoma, and breast cancer. Interestingly, these tumors also exhibit increased expression of HSF1 in patient tumor samples. However, the tumors with HSPA6 were associated with high TMB levels.

Interestingly, HSPA6 expression was also increased in TNBC cell lines BT-549 and MDA-MB-231 tumors. These findings suggest that HSPA6 is a novel TQ-targeted gene. Ultimately, the HSPA6 marker may prove to be a promising diagnostic and prognostic tool for lung cancer patients. But until then, more studies are needed to confirm its utility in lung cancer.

HSPA2 is another growth-promoting factor. Despite its role in lung cancer, little is known about how it affects tumor growth and resistance. However, recent studies have demonstrated that HSPA2 can reduce tumor cell proliferation in NSCLC cells, which suggests a role for the protein in treating the disease. It is still unclear whether or not HSPA3 inhibition can help treat lung cancer. The researchers hope that they will be able to prove the HSPA6 marker for lung cancer.

The researchers used a plasmid to overexpress HSPA6 in U251 cells. A negative control was used as the control. These experiments were repeated three times to confirm that the HSPA6 gene was overexpressed in lung cancer cell lines. In addition, HSPA6 expression was lower in U118 cells that were transfected with a knockdown plasmid. This result was confirmed by qPCR of HSPA6.

HSPA6 Marker for ovarian cancer

One way to test for ovarian cancer is by performing a blood test called an HSPA6 Marker. This tumor marker is overexpressed in epithelial ovarian cancer cells, but small amounts are found in healthy blood. Depending on the level, it can indicate a benign ovarian tumor or a sign of ovarian cancer. A high level may mean the cancer is advanced, but a low level can also mean the cancer is not.

A new study found that a single gene expression level of HSPA6 was associated with poor prognosis in glioma patients. This is consistent with a dual role of HSPA6 in cancer. It acts both as a tumor suppressor and a prosurvival gene in cancer cells. Interestingly, high levels of HSPA6 were associated with a shorter survival time in glioma patients. However, this evidence was not confirmed in dish-based cultures.

RNA-sequencing analysis of cells from SGC7901 tumors showed increased HSPA6 expression. Overexpression of ARHGEF10L induced cell proliferation and migration in HeLa cells, and also elevated HSPA6 expression. These results suggest that ARHGEF10L may play a role in ovarian tumorigenesis. Moreover, ARHGEF10L is a novel tumor-related gene.

The mRNA expression of HSPA6 was compared to a control gene, GAPDH. This endogenous gene is responsible for apoptosis in women. The HSPA6 mRNA level was normalized to GAPDH mRNA expression. After performing the experiments, the samples were analyzed by western blotting. Once the results were determined, the markers of HSPA6 were further validated.

In addition to MMP3, MMP7 and CD44 are also involved in tumor invasion and metastasis. The presence of CD44 or HSPA6 in ovarian cancer cells may serve as a tumor-stem cell marker. Moreover, higher activity of aldehyde dehydrogenase-family member A1 can also be used to identify ovarian cancer stem cells.

In the previous study, HSPA6 and DNAJC20 were associated with poor prognosis in ovarian cancer. The results showed that the overexpression of DNAJC20, CCT1 and CCT6A was related to a worse prognosis. The DNAJC20 and CCT6A expression levels were not statistically significant, but their presence in cancer cells was associated with an enhanced risk of disease progression and mortality.

HSPA6 Marker for prostate cancer

A high expression of the HSPA6 protein in the prostate is associated with a high risk for prostate cancer. The HSPA6 protein is a member of the heat shock protein family. Other members of this family include HSP13, HSP60, HSP90, and HSP90BAN1. Although the expression of these proteins was upregulated in tumour tissues, their levels were relatively low in non-tumour tissue.

HSPA6 induction was associated with the upregulation of other HSP70 proteins. It is not clear why HSPA6 induction occurs but it is possible that it may be a more specific marker of HSP90 inhibition than the other HSP70 proteins. For this reason, further research is needed to confirm the potential of this marker for prostate cancer. While there are no definitive tests for the detection of HSPA6 in prostate cancer, it remains an exciting area of investigation.

To study the effects of 17-AAG on prostate cancer cell lines, various concentrations of the compound were applied to the cells. Then, the levels of HSPA6 and Actin proteins were determined using Western Blot analysis. In contrast, the HSPA6 protein levels were significantly increased when the cells were treated with the drug 17-AAG at the IC50. These findings indicate that a high-concentration of 17-AAG induces the expression of HSPA6 in prostate cancer.

The binding of HSF1 on HSPA6 differed between cancer and heat shock-shock response. In cancer cells, HSF1 only weakly bound HSPA6 mRNA. Moreover, a meta-analysis of over 12,000 gene expression experiments shows that HSF1 depletion did not increase the level of HSPA6 transcript. Therefore, HSPA6 is an essential protein for cancer patients.

The presence of a HSPA6 Marker for prostate cancer could help physicians monitor patients who may be at risk for the disease. Prostate cancer is often characterized by high HSP-6 protein levels. These proteins are involved in the cell cycle and are important in the survival of prostate cancer cells. Researchers are currently studying the role of HSP6 in prostate cancer. However, the role of the HSPA6 Marker is not yet clear.

The HSPA6 Marker is a cancer gene, which means that it regulates prostate-related hormones. This protein has been associated with prostate-related hormones and amplification of the gene. However, HSPA6 is also associated with a decreased expression of c-Jun N-terminal kinase in cancer. Therefore, cancer patients with a high HSPA6 Marker can expect to receive more effective treatment options for prostate-related symptoms.